Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Capricor Therapeutics (CAPR) EBIT Margin (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of EBIT Margin data on record, last reported at 389970.92% in Q3 2025.

  • For Q3 2025, EBIT Margin fell 38939568.0% year-over-year to 389970.92%; the TTM value through Sep 2025 reached 7734.58%, up 786222.0%, while the annual FY2024 figure was 425.65%, 33002.0% down from the prior year.
  • EBIT Margin reached 389970.92% in Q3 2025 per CAPR's latest filing, down from 200103.71% in the prior quarter.
  • Across five years, EBIT Margin topped out at 675.27% in Q4 2024 and bottomed at 389970.92% in Q3 2025.
  • Average EBIT Margin over 5 years is 40745.67%, with a median of 404.86% recorded in 2022.
  • Peak YoY movement for EBIT Margin: surged 450397bps in 2021, then tumbled -38939568bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 2490.75% in 2021, then soared by 66bps to 840.33% in 2022, then soared by 99bps to 10.6% in 2023, then soared by 6471bps to 675.27% in 2024, then tumbled by -57850bps to 389970.92% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 389970.92% in Q3 2025, 200103.71% in Q1 2025, and 675.27% in Q4 2024.